Peaches Biotech Accelerates With Five Drug Launches by 2027

Peaches Biotech is getting ready to go to market. The Spanish biotech company plans to launch its first five drugs in the next five years, Juan Carlos De Gregorio, CEO of the company, has confirmed.

The first of these will be launched on the market in 2024 and, from then on, there will be an annual launch. This cadence of launches will be possible thanks to the technology used by Peaches Biotech, which works through a platform of biological drugs and cell cultures. This process means that, once the safety of the first launch has been proven, the company can accelerate the development of subsequent drugs, according to De Gregorio. The go-to-market strategy has been articulated with the idea of licensing production with big pharma.

The first of these drugs is PRS CK-Storm, which will start a clinical trial in various hospitals in the Madrid region in the coming months. The objective of this drug is to treat cytokine storm.

Find more about Peaches Biotech and read the latest business headlines with our companion app. Born2Invest mobile app makes it easy for you to keep informed, to intuitively move from story to story, and from section to section. Our clean design lets you read articles without clutter, and use the app with no limits on how many articles you can view.

Peaches Biotech has an agreement with Harvard University

Initially, the treatment will be aimed at patients with Covid-19, but the company intends to apply it to other pathologies where cytokine storms occur, such as pancreatitis or those caused by other septic infections. The company has divided its work into two lines of patents based on cell bioculture.

The first is aimed at the regeneration of muscle and bone tissue, while the other is focused on the treatment of different types of solid tumors, with an emphasis on pancreatic cancer. The Madrid-based company has agreements with various organizations and universities. These include collaboration with the University Hospital of Fuenlabrada and Harvard University in the United States.

Peaches Biotech has more than 40 employees and is headquartered in Madrid

At the Madrid center, Peaches Biotech is developing a bio incubator focused on research and innovation (R&D) and aims to promote translational projects in the areas of oncology, hematology, and advanced therapies. At Harvard, the biotech company collaborates in pancreatic cancer research.

The company has more than forty employees and, apart from its headquarters in Madrid, has a laboratory in Fuenlabrada. Peaches Biotech also plans to open a production plant in Bilbao.

__

(Featured image by ernestoeslava via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, sthttps://pixabay.com/photos/laboratory-care-health-medical-2821207/aff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.